The Impact of APOL1 on Donation Uncertainty in PLDs

The implementation of Apolipoprotein L1 (APOL1) genetic testing and counseling does not result in a reduction in the number of living kidney donors.

The findings address a critical concern within transplant medicine regarding whether the disclosure of genetic risk variants would deter potential living donors from proceeding with the donation process.

Potential living donors typically express a strong desire to donate to improve the health of their friends or family members. However, research indicates that many of these individuals maintain a level of uncertainty regarding the decision to donate.

The integration of APOL1 testing into the screening process is designed to enhance the clinical evaluation of a donor’s risk of developing kidney failure following the donation.

From an operational perspective, the stability of the donor pool despite the introduction of genetic risk data suggests that the motivation to assist a loved one outweighs the perceived risks revealed through genetic counseling.

For healthcare institutions and transplant centers, this indicates that genetic screening can be utilized to provide more comprehensive health evaluations for donors without creating a bottleneck in the supply of available organs.